Trump’s tariff threat on generic drugs: Why this matters for Indian pharma companies
A phased tariff schedule on generic pharmaceutical imports into the US has been outlined, with a two-year duty-free window followed by escalating rates
Indian pharmaceutical companies, which supply a large share of the generic drugs used in the US, are assessed as the most exposed exporters to this schedule
The tariff threat is set against India's structural role as a major global supplier of low-cost generics, built on domestic regulatory approval capacity and export infrastructure developed over decades
Analysts note that Indian firms with existing US-based manufacturing facilities may be comparatively insulated once the higher tariff tiers take effect
The development has renewed attention on India's own import dependence for pharmaceutical raw materials, even as its finished-generics exports face tariff risk
Section 232 of the US Trade Expansion Act, 1962 — The Legal Basis for the Tariff
Section 232 lets the US President adjust tariffs, quotas or other import restrictions once the Department of Commerce finds that a category of imports threatens national security. It is separate from ordinary anti-dumping or countervailing duty processes, which require proof of unfair trade practices.
Key Details
- A Section 232 investigation into pharmaceuticals and active pharmaceutical ingredients (APIs) was opened by the US Department of Commerce in April 2025
- An earlier proclamation in April 2026 imposed a 100% tariff on patented (branded) drugs and associated APIs on national-security grounds, while generics and biosimilars were exempted at that time
- The generic-drug schedule extends this same Section 232 framework: zero tariff for roughly two years, then 100%, then 200%
- Because it rests on a national-security finding rather than a trade-remedy finding, this route allows the US to bypass its standard Most Favoured Nation (MFN) obligation under GATT Article I, subject to challenge under the GATT Article XXI security exception
The threatened generics tariff is not a standalone measure — it is the next tranche of a Section 232 pharmaceutical framework that began with patented drugs, now extended to the segment where India holds its largest global market share.
Production Linked Incentive (PLI) Scheme for Bulk Drugs — India's Import-Substitution Effort
India remains heavily import-dependent on China for Key Starting Materials (KSMs), Drug Intermediates and Active Pharmaceutical Ingredients, even as it dominates global finished-generics exports — a structural dependency the government has targeted through a dedicated incentive scheme.
Key Details
- The PLI Scheme for Promotion of Domestic Manufacturing of Critical KSMs/Drug Intermediates and APIs was launched on 20 March 2020, with a financial outlay of ₹6,940 crore for FY2020-21 to FY2029-30, covering 41 identified bulk drugs with high import dependence
- It runs alongside a separate Bulk Drug Parks scheme, which supports common infrastructure for API manufacturing clusters in selected states
- As of recent reporting, over 40 projects covering more than 30 of the identified bulk drugs have been approved, aimed at reducing reliance on imported Chinese APIs
- The scheme is administered by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers
A US tariff squeeze on India's finished-generics exports exposes the flip side of the same vulnerability the PLI-API scheme was designed to fix — India's pharmaceutical export strength sits atop an upstream API supply chain that is itself import-dependent, chiefly on China.
Abbreviated New Drug Application (ANDA) — Why India Dominates US Generic Supply
The regulatory pathway that lets Indian manufacturers sell generics in the US is the Abbreviated New Drug Application process, administered by the US Food and Drug Administration (USFDA), which does not require a company to repeat costly clinical trials already done for the original branded drug.
Key Details
- An ANDA applicant must demonstrate bioequivalence to an already-approved reference (branded) drug rather than submit fresh safety and efficacy trial data, making generic entry significantly cheaper than for a new drug
- India's domestic regulator, the Central Drugs Standard Control Organisation (CDSCO) under the Directorate General of Health Services, Ministry of Health and Family Welfare, runs a comparatively faster domestic approval process, which has helped Indian firms scale manufacturing before pursuing USFDA approval
- India supplies an estimated 40% of generic drugs consumed in the US by volume, according to USFDA data, while accounting for around 20% of global generic drug supply overall
- Indian plants are subject to periodic USFDA facility inspections; adverse inspection findings (warning letters, import alerts) have historically been a bigger near-term risk to Indian pharma exports than tariff policy
India's generics dominance is a function of ANDA-based regulatory efficiency built up over two decades — a competitive advantage that a tariff schedule does not erase, but which raises landed costs enough to threaten the low-margin, high-volume model on which that dominance rests.
- Section 232 pharmaceutical investigation opened: April 2025; patented-drug tariff proclamation: April 2026 (100%, generics exempted at that time)
- Generic drug tariff schedule: 0% for approximately two years, then 100% for one year, then 200% thereafter
- PLI Scheme for Bulk Drugs/KSM/API: launched 20 March 2020; outlay ₹6,940 crore; covers 41 identified bulk drugs
- India's share of US generic drug supply by volume: approximately 40% (USFDA data)
- India's pharmaceutical exports to the US: approximately US $8.7-9.7 billion (FY2024-25), roughly a third of India's total pharma exports [figures vary slightly by source]
- India's total pharmaceutical exports: over US $30 billion annually